Research on patent quality of Chinese listed traditional Chinese medicine enterprises from R&D investment perspective.
10.19540/j.cnki.cjcmm.2019.0024
- Author:
Ya-di CAO
1
;
Rui-Juan GONG
1
;
Ning CHEN
1
;
Wei LIU
1
Author Information
1. School of Management,Beijing University of Traditional Chinese Medicine Beijing 100029,China.
- Publication Type:Journal Article
- Keywords:
listed enterprises;
patents;
research and development investment;
traditional Chinese medicine
- MeSH:
Drugs, Chinese Herbal;
Inventions;
Medicine, Chinese Traditional
- From:
China Journal of Chinese Materia Medica
2019;44(6):1284-1288
- CountryChina
- Language:Chinese
-
Abstract:
In recent years,the number of patent applications for traditional Chinese medicine( TCM) inventions has increased rapidly,but the authorization rate has declined. Listed TCM enterprises are a group of active innovators in this field,so this paper analyzes their patent quality by combining patent application and authorization with R&D investment of enterprises in order to explore a practical way to improve the quality of TCM patents. The conclusions are as follows: the R&D investment of listed TCM enterprises is insufficient and the gap between enterprises is large; the number of patent applications is within a reasonable range,but some enterprises still have abnormal patent applications,and patent quality needs to be improved; in addition,the patent operation capacity of enterprises still needs to be improved. In this phenomenon,enterprises should improve R&D investment,strengthen the level of technological innovation,improve the ability of patent operation,and consciously eliminate the output of " abnormal patents"; the patent administrative department should optimize policy direction which is beneficial to the improvement of patent quality,grasp the normal and reasonable examination scale,and jointly improve the quality of TCM patents.
